Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC)

0 avis

Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC)

Archive ouverte

Edité par CCSD ; SPRINGER, 233 SPRING ST, NEW YORK, NY 10013 USA -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

(18)F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Archive ouverte | Cochet, Alexandre | CCSD

International audience. PURPOSE: The objective of this study was to assess the impact on management and the prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for initial stagin...

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST

Archive ouverte | Depardon, Edouard | CCSD

International audience. AimEvaluate response and predict prognosis of patients with newly diagnosed metastatic breast cancer treated with first line systemic therapy using European Organization for Research and Trea...

Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18 F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response

Archive ouverte | Humbert, Olivier | CCSD

International audience. Early changes in tumor glucose metabolism (SUVmax) and in tumor blood flow (BF) have been evaluated separately for monitoring breast cancer response to neoadjuvant chemotherapy (NAC). This st...

Chargement des enrichissements...